Page 15 of 27

PA27.{14,16} | Renal & Urothelial Tumours — SDL Guide (Part 3)

Urothelial (Transitional Cell) Carcinoma — Introduction and Risk Factors

A three-panel medical diagram summarizes urothelial carcinoma sites, epidemiology, and major risk factors centered on the bladder. — **Panel A:** Anterior urinary tract showing kidney, renal pelvis, ureter, urinary bladder, proximal urethra, highlighted urothelium, transitional epithelium inset, and bladder as the commonest UC site.. **Panel B:** Epidemiology summary showing male:female ratio 3:1, peak incidence in the 6th-7th decades, and bladder cancer as the 4th commonest cancer in men.. **Panel C:** Risk-factor map showing cigarette smoking, aromatic amines/aniline dyes, cyclophosphamide, Schistosoma haematobium, and chronic irritation/infection with arrows to the bladder..

Urothelial carcinoma (UC) arises from the transitional epithelium (urothelium) lining the renal pelvis, ureters, bladder, and proximal urethra. The bladder is by far the commonest site (~90% of UC), followed by the renal pelvis, ureter, and urethra.

Bladder cancer is the 4th most common cancer in men in India and worldwide. The male:female ratio is ~3:1; peak incidence is in the 6th–7th decades.

Risk factors — the most important examination topic in urothelial carcinoma:

Risk factor	Comment
Cigarette smoking	Single most important risk factor; 2–4× increased risk; carcinogens excreted in urine concentrate in the bladder
Aromatic amines / aniline dyes	Occupational exposure (textile workers, rubber industry, leather, printing); 2-naphthylamine and benzidine are classic carcinogens; urinary NAT2 slow-acetylator phenotype increases susceptibility
Cyclophosphamide	Metabolite acrolein is directly urotheliotoxic; haemorrhagic cystitis precedes malignancy
Schistosoma haematobium	Associated specifically with squamous cell carcinoma (SCC) of the bladder (not UC); eggs deposited in bladder wall → chronic inflammation → squamous metaplasia → SCC; endemic in Egypt and sub-Saharan Africa
Phenacetin abuse	Renal pelvis UC (analgesic nephropathy)
Pelvic irradiation	Long-term risk of UC

Key teaching point: Schistosomiasis → SCC (not UC). This distinction appears regularly in MCQs.

Urothelial Carcinoma — Morphology, Grading, and Staging

Diagram comparing papillary urothelial carcinoma, flat CIS, grading spectrum, and staging depth in the bladder wall. — **Panel A:** Cut-open bladder showing papillary urothelial carcinoma with exophytic fronds and flat carcinoma in situ as a red velvety mucosal patch, with urothelium, lumen, lamina propria, and muscularis propria labeled.. **Panel B:** WHO grading spectrum showing PUNLMP, low-grade papillary urothelial carcinoma, and high-grade papillary urothelial carcinoma with increasing atypia, architectural disorder, and mitoses.. **Panel C:** Bladder wall staging diagram showing Ta, Tis, T1, and T2 relative to basement membrane, lamina propria, and muscularis propria, grouped as NMIBC versus MIBC..

UC exists in two broad growth patterns with fundamentally different biology:

1. Papillary carcinoma
• Exophytic papillary fronds projecting into the bladder lumen
• Most common pattern; often low-grade
• Presents as painless haematuria; diagnosed on cystoscopy + biopsy

2. Flat carcinoma in situ (CIS)
• Carcinoma in situ (CIS): flat, high-grade dysplastic urothelium confined to the mucosa; no exophytic growth
• Appears as red, velvety, ill-defined mucosal lesion on cystoscopy
• Despite being non-invasive by definition, CIS is high-grade and carries a significant risk of progression to muscle-invasive disease

Grading (WHO 2004/2016):
• PUNLMP (papillary urothelial neoplasm of low malignant potential): papillary lesion, minimal cytological atypia
• Low-grade papillary UC: mild-moderate atypia, orderly architecture
• High-grade papillary UC: marked atypia, disordered architecture, frequent mitoses

Staging — the critical clinical division:

Stage	Description	Clinical term
Ta	Papillary, non-invasive (above basement membrane)	Non-muscle-invasive (NMIBC)
Tis (CIS)	Flat CIS, non-invasive	Non-muscle-invasive
T1	Invades lamina propria (subepithelial connective tissue)	Non-muscle-invasive
T2	Invades muscularis propria (detrusor)	Muscle-invasive (MIBC)
T3	Invades perivesical fat	Muscle-invasive
T4	Invades adjacent organs	Muscle-invasive

The T2 boundary (muscularis propria invasion) is the critical threshold: NMIBC is managed with transurethral resection ± intravesical BCG; MIBC requires radical cystectomy ± systemic chemotherapy.

Side-by-side H&E histology comparison of low-grade papillary urothelial carcinoma with papillary fronds and carcinoma in situ with flat full-thickness dysplasia but no stromal invasion. — **Panel A:** Low-grade papillary urothelial carcinoma showing papillary frond, fibrovascular core, mildly atypical urothelium, and basement membrane.. **Panel B:** Carcinoma in situ showing flat urothelium, full-thickness dysplasia, pleomorphic nuclei, basement membrane, stroma/lamina propria, and label 'CIS — no stromal invasion'..

Urothelial Carcinoma — Clinical Features and Field Effect

Diagram showing urothelial carcinoma field effect across the urinary tract, its symptoms, recurrence, upper tract risk, and lymphatic and haematogenous spread. — **Panel A:** Continuous urothelial lining from renal pelvis to urethra, urine-borne carcinogens, smoking exposure, multifocal red tumour foci in renal pelvis, ureter, bladder, and urethra.. **Panel B:** Bladder cross-section showing painless haematuria, irritative symptoms, cystoscopy red flag, and CIS with diffusely abnormal urothelium.. **Panel C:** Post-resection NMIBC timeline showing residual urothelium, new tumour formation, high recurrence rate around 70% at 5 years, and lifelong cystoscopic surveillance.. **Panel D:** Bladder urothelial carcinoma with possible synchronous or metachronous renal pelvis and ureter tumours, including contralateral upper tract involvement risk.. **Panel E:** Lymphatic spread to obturator, internal iliac, and common iliac nodes, with late haematogenous spread to liver, lungs, and bone..

Presentation:
• Painless haematuria — the hallmark symptom; any age, any sex; blood in urine is a red-flag symptom that mandates cystoscopy
• Irritative symptoms — frequency, urgency, dysuria: especially with CIS (the urothelium is diffusely abnormal)
• Obstructive symptoms and hydronephrosis with ureteric involvement

The field effect and its clinical consequences:

The field effect (field cancerisation) describes the tendency of the entire urothelium — from renal pelvis to urethra — to undergo malignant transformation when exposed to carcinogens excreted in urine. Consequences:

Multifocality: multiple synchronous tumours at different urothelial sites at presentation
High recurrence rate: even after complete resection of a NMIBC, carcinogens bathing residual urothelium drive new tumours; recurrence rate ~70% at 5 years
Surveillance by cystoscopy: mandatory lifelong follow-up
Upper tract UC: patients with bladder UC have a 2–4% risk of synchronous or metachronous renal pelvis / ureter tumours (contralateral involvement possible)

This field effect concept explains why bladder cancer behaves so differently from solid organ tumours where surgical excision is often curative: the at-risk surface is vast, and the carcinogen exposure is continuous as long as the patient smokes.

Lymphatic spread: to obturator, internal iliac, and common iliac nodes.
Haematogenous spread: liver, lungs, bone (late).

SELF-CHECK

A 62-year-old male textile dye worker presents with three separate episodes of painless haematuria over 6 months. Cystoscopy reveals two papillary lesions and one red velvety mucosal area. Biopsy of the velvety area shows full-thickness urothelial atypia without stromal invasion. Which statement about his disease is MOST accurate?

A. The velvety lesion (CIS) is low-grade and unlikely to progress to muscle-invasive disease

B. The most probable occupational carcinogen is acrolein from cyclophosphamide metabolism

C. The multifocal pattern reflects field cancerisation from carcinogens excreted in urine

D. Schistosoma haematobium is the most likely aetiological agent in this case

Reveal Answer

Answer: C. The multifocal pattern reflects field cancerisation from carcinogens excreted in urine

Multifocal synchronous tumours (papillary + CIS) in a patient with occupational aromatic amine exposure perfectly illustrate field cancerisation — the entire urothelium is at risk because carcinogens concentrate in urine and bathe the whole surface. CIS is high-grade (not low-grade) and carries significant progression risk. Acrolein is a cyclophosphamide metabolite; aromatic amines (2-naphthylamine, benzidine) are the relevant dye-industry carcinogens. Schistosomiasis causes SCC, not UC.

CLINICAL PEARL

Occupation → carcinogen → tumour type: the exam matrix

Exposure	Carcinogen	Tumour
Textile / dye workers	2-naphthylamine, benzidine (aromatic amines)	Urothelial carcinoma
Smoking	β-naphthylamine + polycyclic aromatic hydrocarbons	Urothelial carcinoma
Cyclophosphamide therapy	Acrolein	Urothelial carcinoma
Schistosoma haematobium	Chronic mucosal injury → squamous metaplasia	Squamous cell carcinoma

Note that schistosomiasis → SCC, not UC. This distinction is reliably tested. Also remember: painless haematuria in any adult = cystoscopy mandatory until proven otherwise — bladder cancer is too important to miss.

Summary Table — Comparing the Major Renal Tumours

Three-panel comparison diagram showing clear cell RCC, Wilms tumour, and urothelial carcinoma by age group, anatomical site, key gene, gross appearance, and microscopic features. — **Panel A:** Clear cell renal cell carcinoma: adult age group, renal cortex upper pole, VHL 3p25 mutation, yellow haemorrhagic gross tumour, clear lipid-rich cells on microscopy.. **Panel B:** Wilms tumour: child age group, tumour involving entire kidney, WT1 11p13 mutation, fish-flesh mass with pseudocapsule, triphasic microscopic pattern.. **Panel C:** Urothelial carcinoma: adult age group, bladder much more common than renal pelvis, no single dominant gene, papillary or flat lesion, atypical urothelial cells..

Feature	Clear cell RCC	Wilms tumour	Urothelial carcinoma
Age group	Adults (6th–7th decade)	Children (2–5 years)	Adults (6th–7th decade)
Site	Renal cortex (upper pole)	Entire kidney	Bladder >> renal pelvis
Key gene	VHL (3p25)	WT1 (11p13)	None single dominant
Gross	Yellow, haemorrhagic	Fish-flesh, pseudocapsule	Papillary or flat
Micro	Clear lipid-rich cells, sinusoidal vasculature	Triphasic (blast/epi/stroma)	Papillary fronds or flat CIS
Hallmark symptom	Haematuria + flank mass	Painless abdominal mass	Painless haematuria
Spread	Renal vein/IVC; cannonball lungs	Lymph nodes; haematogenous	Lymphatic; field recurrence
Key risk factor	Smoking, VHL mutation, obesity	WT1 germline loss	Smoking, aromatic amines